Otonomy Inc
F:7OT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Otonomy Inc
Accrued Liabilities
Otonomy Inc
Accrued Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
O
|
Otonomy Inc
F:7OT
|
Accrued Liabilities
$8.5m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Accrued Liabilities
$32.3B
|
CAGR 3-Years
5%
|
CAGR 5-Years
3%
|
CAGR 10-Years
10%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Accrued Liabilities
$13.1B
|
CAGR 3-Years
8%
|
CAGR 5-Years
6%
|
CAGR 10-Years
12%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Accrued Liabilities
$3.6B
|
CAGR 3-Years
2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
4%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Accrued Liabilities
$14.4B
|
CAGR 3-Years
2%
|
CAGR 5-Years
2%
|
CAGR 10-Years
3%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Accrued Liabilities
$19.8B
|
CAGR 3-Years
26%
|
CAGR 5-Years
24%
|
CAGR 10-Years
19%
|
|
Otonomy Inc
Glance View
Otonomy, Inc. operates as a biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 51 full-time employees. The company went IPO on 2014-08-13. The firm is focused on the development of therapeutics for neurotology. The firm pipeline includes OTIPRIO, OTIVIDEX, OTO-313, and OTO-413. OTIPRIO is a single-dose, physician-administered antibacterial for the treatment of pediatric patients with bilateral otitis media with effusion undergoing TTP surgery for the treatment of patients with acute otitis externa (AOE). OTIVIDEX is a sustained-exposure formulation of the steroid dexamethasone in development for the treatment of Menieres disease. OTO-313 is a sustained-exposure formulation of gacyclidine, a potent and selective N-Methyl-D-Aspartate (NMDA) receptor antagonist, in in Phase II for tinnitus. OTO-413 is a sustained-exposure formulation of brain-derived neurotrophic factor (BDNF) in Phase IIa development for the repair of cochlear synaptopathy, an underlying pathology in age-related and noise-induced hearing loss. OTO-825, a gene therapy for congenital hearing loss.
See Also
What is Otonomy Inc's Accrued Liabilities?
Accrued Liabilities
8.5m
USD
Based on the financial report for Sep 30, 2022, Otonomy Inc's Accrued Liabilities amounts to 8.5m USD.
What is Otonomy Inc's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
-1%
Over the last year, the Accrued Liabilities growth was -8%. The average annual Accrued Liabilities growth rates for Otonomy Inc have been -5% over the past three years , -1% over the past five years .
